The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product. Before prescribing any product mentioned in this Register, healthcare professionals should consult prescribing information for the product approved in their country.

Study No.: SND103285
Title: A Ten-Week, Multicenter, Randomized, Double-Blind, Placebo- and Active-controlled, Parallel-Group, Flexible-Dose Study Evaluating the Efficacy, Safety and Tolerability of GSK372475, a new Chemical Entity (NCE) or Extended Released Venlafaxine (150 mg/day to 225 mg/day) Compared to Placebo in Adult Subjects Diagnosed with Major Depressive Disorder
Rationale: The primary purpose of this study was to evaluate the efficacy, safety, and tolerability of the NCE or extended release venlafaxine compared with placebo in adult subjects diagnosed with major depressive disorder (MDD). This summary includes data for venlafaxine and placebo group. The NCE development was terminated in April 2009. But if the development re-start, the results will be added if and when the NCE will be approved and marketed.
Phase: II
Study Period: 17 April 2007 to 03 December 2008
Study Design: A 10-week randomised, multicentre, double-blind, parallel-group, placebo- and active-controlled, flexible-dose study.
Centres: Thirty-six centres in 12 countries; 6 centres in Canada, 3 in Australia, 4 in Germany, 4 in India, 4 in South Africa, 3 in Poland, 2 in Belgium, 2 in Bulgaria, 2 in Estonia, 2 in Finland, 2 in France and 2 in Slovakia.
Indication: Major Depressive Disorder (MDD)
Treatment: Subjects were randomised in a 1:1:1 ratio to 1 of 3 treatment regimens: NCE, venlafaxine XR 75 mg/day to 225 mg/day, or placebo. All subjects were to receive Dose Level (DL) 1 for the first week of the Treatment Phase. At the Week 1 Visit, the dose was increased to DL2 for 3 weeks. At the Week 4 Visit, if in the investigator's jud gment, the subject was not experiencing any troublesome adverse events (AEs) or symptoms and had not met response criteria, the dose was to be increased to DL3 for the duration of the Treatment Phase.
Objectives: The key objective of the study was to evaluate the antidepressant efficacy of NCE compared with placebo in subjects diagnosed with MDD.
Primary Outcome/Efficacy Variable: The key efficacy endpoints were change from Randomisation at Week 10 in the 6-item Bech scale from the Hamilton Depression Rating Scale – 17 item (HAMD-17) and the Inventory of Depressive Symptomatology – Clinician-Rated (IDS-CR) total score.
Secondary Outcome/Efficacy Variable(s): The secondary efficacy variables were: Change from Randomisation at Weeks 1, 2, 4, 6 and 8 in the IDS-CR total score and the 6-item Bech scale extracted from the HAMD-17; Change from Randomisation at Weeks 1, 4 and 10 in the IDS-SR total score, the 16-item Quick Inventory of Depressive Symptomatology – Self Report version (QIDS-SR 16) total score and the 18-Item Motivation and Energy Inventory (MEI) Short Form total score; Change from Randomisation at Weeks 1, 2, 4, 6, 8 and 10 in the HAMD-17 total score, the 16-item Quick Inventory of Depressive Symptomatology – Clinician Rating version (QIDS-CR 16) total score, item 5 (feeling sad) of the IDS-CR, item 1 (depressed mood) of the HAMD-17 and the Clinical Global Impression - Severity of Illness (CGI-S); Change from Randomisation at Weeks 1, 2, 3, 4, 5, 6, 8 and 10 of the 5-item IDS subscale consisting of item 19 (General interest/involvement), item 20 (Energy/fatiguability), item 21 (Pleasure/Enjoyment), item 22 (Sexual interest), item 30 (Leaden paralysis/physical energy), (Pleasure, Interest, Energy); Percentage of responders at Weeks 1, 2, 4, 6, 8, and 10 in terms of IDS-CR total score and HAMD-17 total score; Percentage of remitters at Weeks 1, 2, 4, 6, 8, and 10 in terms of IDS-CR total score and HAMD-17 total score; Time to maintained antidepressant response in terms of HAMD-17 total score and IDS-CR total score; Time to maintained remission in terms of IDS-CR total score and HAMD-17 total score; Percentage of Clinical Global Impression - Global Improvement (CGI-I) responders (defined as subjects with a score of 1 [very much improv ed] or 2 [much improved] i n the CGI-I) at Weeks 1,

2, 4, 6, 8 and 10;
Subject Satisfaction with Study Medication Question score at Week 10;
Change from Randomisation at Weeks 4 and 10 in the Changes in Sexual Functioning Questionnaire 14-item Short Form.

Statistical Methods: The primary analyses comprised a Mixed Model Repeated Measures (MMRM) analysis to investigate the difference between the NCE and placebo and venlafaxine XR and placebo at the end of the study in the above 2 key efficacy endpoints.
Secondary efficacy analyses comprised the same MMRM model that was fitted on the 2 key endpoints, a logistic regression to investigate the percentage of responders/remitters and a survival analysis to investigate time to response/remission.
All analyses presented were performed on the Intent-to treat (ITT) population defined as all subjects who gave informed consent, were randomised, received at least 1 dose of double blind medication and for whom at least 1 post randomisation assessment was available.

Study Population: Key inclusion criteria were:
Male and non-pregnant, non-lactating females, aged 18 to 64 years, inclusive, with a diagnosis of major depressive episode (MDE) associated with MDD meeting DSM-IV-TR criteria were eligible for inclusion in this study. Subjects must also, in the investigator's opinion based on clinical history, have met DSM-IV-TR criteria for their current MDE for at least 12 weeks but no greater than 24 months. Subjects required an Interactive Voice Response System (IVRS) Inventory of Depressive Symptomatology – Self-Report (IDS-SR) total score of at least 40 at the Screening and Randomisation Visits and a Clinical Global Impression – Severity of Illness (CGI-S) score of at least 4 at the Randomisation Visit. Female subjects of child-bearing potential were eligible to enter the study if they agreed to satisfy 1 of the protocol specified methods of contraception.
Key exclusion criteria were:
DSM IV Axis I disorder other than MDD, secondary diagnosis of anxiety disorders are permissible
Any DSM IV Axis II disorder which could interfere with non-responsiveness to pharmacotherapy
Current diagnosis of dementia
Unstable medical disorder, risk of suicide, history of substance abuse or dependence

	Placebo	**Venlafaxine XR**
Number of Subjects:		
Planned, N	126	126
Randomised, N	126	134
ITT Population, N	126	133
Subject disposition (ITT Population)		
Completed, n (%)	84 (67)	84 (63)
Total Number Subjects Withdrawn, n (%)	42 (33)	49 (37)

Withdrawn due to Adverse Events, n (%)	7 (6)	19 (14)
Withdrawn due to a Protocol Violation, n (%)	8 (6)	12 (9)
Voluntary Subject Withdrawal, n (%)	10 (8)	3 (2)
Lost to Follow-up, n (%)	5 (4)	8 (6)
Lack of efficacy, n (%)	5 (4)	3 (2)
Non-compliance, n (%)	3 (2)	0
Withdrawn for other reasons n (%)	4 (3)	4 (3)
Demographics	**Placebo**	**Venlafaxine XR**
N (ITT)	126	133
Females:Males	80:46	81:52
Mean Age, years (SD)	41.9 (11.79)	43.0 (11.19)
Not Hispanic/Latino, n (%)	125 (>99)	132 (>99)
Primary Efficacy Results (ITT Population):		
	Placebo (N=126)	**Venlafaxine XR (N=133)**
6-item Bech scale from HAMD-17 (MMRM analysis)		
Baseline, mean (SD)	12.3 (2.44)	11.8 (2.31)
Change from Randomisation to Week 10 (Least Squares [LS] mean)	-6.40	-7.97
Difference versus placebo	-	-1.56
90% Confidence Interval	-	(-2.42, -0.71)
p-value	-	0.003
IDS-CR total score (MMRM analysis)		
Baseline, mean (SD)	44.7 (9.67)	43.4 (9.01)
Change from Randomisation to Week 10 (LSmean)	-24.06	-28.50
Difference versus placebo	-	-4.45
90% Confidence Interval	-	(-7.26, -1.64)

p-value	-	0.010
Secondary Outcome Variables (ITT Population):		
	Placebo (N=126)	**Venlafaxine XR (N=133)**
6-item Bech scale from HAMD-17 (summary statistics)		
Change from Randomisation to Week 1 (mean [SD])	-1.4 (2.40)	-1.7 2.37
Range	-9 to 3	-9 to 2
Change from Randomisation to Week 2 (mean [SD])	-2.9 (3.14)	-3.1 (3.40)
Range	-12 to 3	-12 to 6
Change from Randomisation to Week 4 (mean [SD])	-4.3 (3.46)	-4.8 (3.03)
Range	-13 to 4	-13 to 4
Change from Randomisation to Week 6 (mean [SD])	-5.5 (3.79)	-6.8 (3.28)
Range	-15 to 4	-16 to 3
Change from Randomisation to Week 8 (mean [SD])	-6.2 (4.07)	-7.7 (3.56)
Range	-17 to 2	-16 to 1
Change from Randomisation to Week 10 (mean [SD])	-6.5 (4.06)	-8.0 (3.58)
Range	-15 to 3	-17 to 2
IDS-CR total score (summary statistics)		
Change from Randomisation to Week 1 (mean [SD])	-5.9 (8.87)	-6.5 (8.34)
Range	-42 to 11	-32 to 9
Change from Randomisation to Week 2 (mean [SD])	-10.7 (9.93)	-11.9 (10.75)
Range	-38 to 14	-47 to 19
Change from Randomisation to Week 4 (mean [SD])	-15.7 (12.05)	-17.1 (11.21)
Range	-45 to 15	-47 to 10
Change from Randomisation to Week 6 (mean [SD])	-20.5 (13.25)	-24.2 (10.90)

Range	-63 to 9	-56 to 6
Change from Randomisation to Week 8 (mean [SD])	-23.8 (13.53)	-26.9 (10.44)
Range	-66 to 7	-58 to 4
Change from Randomisation to Week 10 (mean [SD])	-24.2 (13.79)	-28.4 (11.56)
Range	-61 to 4	-57 to 0
IDS-SR total score (summary statistics)		
Change from Randomisation to Week 1 (mean [SD])	-11.4 (11.24)	-12.2 (11.77)
Range	-50 to 9	-45 to 8
Change from Randomisation to Week 4 (mean [SD])	-22.2 (15.04)	-24.5 (14.27)
Range	-56 to 16	-51 to 5
Change from Randomisation to Week 10 (mean [SD])	-29.7 (16.36)	-35.1 (13.51)
Range	-69 to 2	-60 to -2
IDS-SR total score (MMRM analysis)		
Change from Randomisation to Week 10 (LSmean)	-29.03	-35.08
Difference versus placebo	-	-6.05
90% Confidence interval	-	-9.53, -2.57
QIDS-CR 16 total score (summary statistics)		
Change from Randomisation to Week 1 (mean [SD])	-2.3 (3.32)	-2.6 (3.47)
Range	-13 to 6	-14 to 6
Change from Randomisation to Week 2 (mean [SD])	-4.1 (3.62)	-4.3 (4.32)
Range	-16 to 4	-14 to 9
Change from Randomisation to Week 4 (mean [SD])	-5.9 (4.73)	-6.2 (4.21)
Range	-18 to 5	-16 to 6
Change from Randomisation to Week 6 (mean [SD])	-7.6 (4.96)	-8.8 (4.32)

Range	-20 to 6	-20 to 5
Change from Randomisation to Week 8 (mean [SD])	-8.9 (5.16)	-9.7 (4.58)
Range	-23 to 3	-21 to 8
Change from Randomisation to Week 10 (mean [SD])	-8.8 (5.26)	-10.3 (4.73)
Range	-21 to 3	-21 to 1
QIDS-CR 16 total score (MMRM analysis)		
Change from Randomisation to Week 10 (LSmean)	-8.82	-10.47
Difference versus placebo	-	-1.65
90% Confidence interval	-	-2.75, -0.55
QIDS-SR 16 total score (summary statistics)		
Change from Randomisation to Week 1 (mean [SD])	-3.7 (4.26)	-4.4 (4.83)
Range	-19 to 6	-21 to 5
Change from Randomisation to Week 4 (mean [SD])	-7.8 (6.05)	-9.0 (5.53)
Range	-21 to 9	-22 to 5
Change from Randomisation to Week 10 (mean [SD])	-10.7 (7.05)	-13.3 (5.32)
Range	-25 to 5	-24 to 3
QIDS-SR 16 total score (MMRM analysis)		
Change from Randomisation to Week 10 (LSmean)	-10.62	-13.29
Difference versus placebo	-	-2.67
90% Confidence interval	-	-4.03, -1.31
MEI 18-item total score (summary statistics)		
Change from Randomisation to Week 1 (mean [SD])	7.0 (13.32)	5.9 (13.58)
Range	-25 to 59	-24 to 63
Change from Randomisation to Week 4 (mean [SD])	17.0 (18.82)	19.0 (19.12)

Range	-16 to 67	-22 to 81
Change from Randomisation to Week 10 (mean [SD])	26.5 (23.12)	35.0 (24.37)
Range	-21 to 85	-25 to 87
MEI 18-item total score (MMRM analysis)		
Change from Randomisation to Week 10 (LSmean)	27.49	34.75
Difference versus placebo	-	7.26
90% Confidence interval	-	2.02, 12.49
IDS-CR Item 5 score (summary statistics)		
Change from Randomisation to Week 1 (mean [SD])	-0.3 (0.68)	-0.4 (0.81)
Range	-3 to 1	-3 to 2
Change from Randomisation to Week 2 (mean [SD])	-0.6 (0.87)	-0.8 (0.91)
Range	-3 to 1	-3 to 1
Change from Randomisation to Week 4 (mean [SD])	-0.8 (0.91)	-1.1 (0.95)
Range	-3 to 1	-3 to 2
Change from Randomisation to Week 6 (mean [SD])	-1.1 (0.97)	-1.5 (0.93)
Range	-3 to 1	-3 to 2
Change from Randomisation to Week 8 (mean [SD])	-1.2 (1.08)	-1.6 (0.89)
Range	-3 to 1	-3 to 3
Change from Randomisation to Week 10 (mean [SD])	-1.3 (1.07)	-1.6 (0.80)
Range	-3 to 1	-3 to 1
IDS-CR Item 5 score (MMRM analysis)		
Change from Randomisation to Week 10 (LSmean)	-1.27	-1.52
Difference versus placebo	-	-0.25
90% Confidence interval	-	-0.44, -0.05

HAMD-17 total score (summary statistics)		
Change from Randomisation to Week 1 (mean [SD])	-3.2 (4.49)	-3.2 (4.33)
Range	-25 to 5	-17 to 5
Change from Randomisation to Week 2 (mean [SD])	-5.6 (5.40)	-6.1 (5.78)
Range	-22 to 6	-25 to 9
Change from Randomisation to Week 4 (mean [SD])	-8.4 (6.47)	-8.9 (5.80)
Range	-24 to 8	-24 to 6
Change from Randomisation to Week 6 (mean [SD])	-11.0 (6.97)	-12.3 (5.95)
Range	-27 to 4	-31 to 4
Change from Randomisation to Week 8 (mean [SD])	-12.7 (7.68)	-14.0 (6.36)
Range	-31 to 7	-32 to 1
Change from Randomisation to Week 10 (mean [SD])	-13.0 (7.32)	-14.9 (6.53)
Range	-29 to 3	-32 to 2
HAMD-17 total score (MMRM analysis)		
Change from Randomisation to Week 10 (mean [range])	-12.60	-14.94
Difference versus placebo (SE)	-	-2.35
95% Confidence Interval	-	-3.84, -0.86
HAMD-17 Item 1 score (summary statistics)		
Change from Randomisation to Week 1 (mean [SD])	-0.3 (0.61)	-0.5 (0.74)
Range	-2 to 1	-3 to 1
Change from Randomisation to Week 2 (mean [SD])	-0.6 (0.79)	-0.8 (1.02)
Range	-3 to 1	-3 to 2
Change from Randomisation to Week 4 (mean [SD])	-1.0 (0.96)	-1.3 (1.02)
Range	-3 to 2	-3 to 1

Change from Randomisation to Week 6 (mean [SD])	-1.2 (1.00)	-1.6 (1.08)
Range	-3 to 2	-4 to 1
Change from Randomisation to Week 8 (mean [SD])	-1.4 (1.14)	-1.8 (1.08)
Range	-4 to 2	-4 to 1
Change from Randomisation to Week 10 (mean [SD])	-1.5 (1.20)	-1.8 (1.01)
Range	-4 to 2	-4 to 1
HAMD-17 Item 1 score (MMRM analysis)		
Change from Randomisation to Week 10 (LSmean)	-1.48	-1.78
Difference versus placebo	-	-0.30
90% Confidence interval	-	-0.52, -0.07
CGI-S (summary statistics)		
Change from Randomisation to Week 1 (mean [SD])	-0.2 (0.62)	-0.3 (0.59)
Range	-4 to 2	-3 to 1
Change from Randomisation to Week 2 (mean [SD])	-0.5 (0.78)	-0.7 (0.85)
Range	-4 to 1	-4 to 0
Change from Randomisation to Week 4 (mean [SD])	-1.0 (1.05)	-1.2 (1.15)
Range	-4 to 0	-5 to 1
Change from Randomisation to Week 6 (mean [SD])	-1.5 (1.21)	-1.8 (1.22)
Range	-5 to 1	-5 to 1
Change from Randomisation to Week 8 (mean [SD])	-1.8 (1.30)	-2.2 (1.21)
Range	-5 to 0	-5 to 0
Change from Randomisation to Week 10 (mean [SD])	-2.0 (1.38)	-2.5 (1.19)
Range	-5 to 0	-5 to 0
CGI-S score (MMRM analysis)		

Change from Randomisation to Week 10 (LSmean)	-1.95	-2.42
Difference versus placebo	-	-0.47
90% Confidence interval	-	-0.76, -0.18
5-item IDS-CR subscale (summary statistics)		
Change from Randomisation to Week 1 (mean [SD])	-1.0 (2.57)	-0.9 (2.29)
Range	-11 to 5	-9 to 6
Change from Randomisation to Week 2 (mean [SD])	-2.1 (2.72)	-2.1 (3.10)
Range	-10 to 3	-10 to 9
Change from Randomisation to Week 4 (mean [SD])	-3.1 (3.32)	-3.5 (3.05)
Range	-14 to 4	-10 to 9
Change from Randomisation to Week 6 (mean [SD])	-4.3 (3.35)	-5.3 (3.17)
Range	-15 to 3	-13 to 9
Change from Randomisation to Week 8 (mean [SD])	-4.9 (3.28)	-5.6 (3.20)
Range	-15 to 1	-13 to 4
Change from Randomisation to Week 10 (mean [SD])	-5.1 (3.75)	-6.1 (3.18)
Range	-15 to 2	-12 to 1
5-item IDS-CR subscale (MMRM analysis)		
Change from Randomisation to Week 10 (mean [range])	-5.33	-6.11
Difference versus placebo (SE)	-	-0.78
95% Confidence Interval	-	-1.57, 0.01
5-item IDS-SR subscale (summary statistics)		
Change from Randomisation to Week 1 (mean [SD])	-3.0 (3.72)	-2.7 (3.59)
Range	-15 to 4	-13 to 7
Change from Randomisation to Week 4 (mean [SD])	-5.2 (4.57)	-5.6 (4.47)

Range	-15 to 8	-15 to 4
Change from Randomisation to Week 10 (mean [SD])	-6.9 (5.42)	-8.4 (4.32)
Range	-15 to 7	-15 to 5
5-item IDS-SR subscale (MMRM analysis)		
Change from Randomisation to Week 10 (mean [range])	-6.80	-8.26
Difference versus placebo (SE)	-	-1.46
95% Confidence Interval	-	-2.51, -0.41
Percentage of responders		
IDS-CR (≥50% reduction from Randomisation in total score)		
Week 1 % responders	5	5
Odds ratio (90% confidence interval)	-	1.02 (0.38, 2.73)
Week 2 % responders	16	16
Odds ratio (90% confidence interval)	-	0.94 (0.52, 1.69)
Week 4 % responders	28	34
Odds ratio (90% confidence interval)	-	1.29 (0.78, 2.13)
Week 6 % responders	48	62
Odds ratio (90% confidence interval)	-	1.70 (1.05, 2.75)
Week 8 % responders	58	67
Odds ratio (90% confidence interval)	-	1.41 (0.87, 2.29)
Week 10 % responders	56	72
Odds ratio (90% confidence interval)	-	1.98 (1.18,3.33)
HAMD-17 (50% reduction from Randomisation in total score)		
Week 1 % responders	4	6
Odds ratio (90% confidence interval)	-	1.37 (0.50, 3.73)

Week 2 % responders	11	13
Odds ratio (90% confidence interval)	-	1.11 (0.58, 2.11)
Week 4 % responders	29	33
Odds ratio (90% confidence interval)	-	1.23 (0.74, 2.04)
Week 6 % responders	42	53
Odds ratio (90% confidence interval)		1.57 (0.96, 2.56)
Week 8 % responders	53	64
Odds ratio (90% confidence interval)	-	1.78 (1.09, 2.92)
Week 10 % responders	59	70
Odds ratio (90% confidence interval)	-	1.72 (1.02, 2.89)
CGI-I (subjects with a CGI-I score of 1 or 2)		
Week 1 % responders	7	7
Odds ratio (90% confidence interval)	-	0.98 (0.44, 2.20)
Week 2 % responders	21	19
Odds ratio (90% confidence interval)	-	0.87 (0.49, 1.56)
Week 4 % responders	41	50
Odds ratio (90% confidence interval)	-	1.47 (0.93, 2.33)
Week 6 % responders	62	73
Odds ratio (90% confidence interval)	-	1.60 (0.97, 2.64)
Week 8 % responders	70	80
Odds ratio (90% confidence interval)	-	1.66 (0.96, 2.85)
Week 10 % responders	67	87
Odds ratio (90% confidence interval)	-	3.31 (1.80, 6.07)

Percentage of remitters		
IDS-CR (subjects with IDS total score ≤14)		
Week 1 % remitters	2	2
Odds ratio (90% confidence interval)	-	1.33 (0.29, 6.21)
Week 2 % remitters	6	4
Odds ratio (90% confidence interval)	-	0.71 (0.27, 1.87)
Week 4 % remitters	12	12
Odds ratio (90% confidence interval)	-	0.85 (0.41, 1.78)
Week 6 % remitters	22	36
Odds ratio (90% confidence interval)		1.78 (1.02, 3.10)
Week 8 % remitters	34	48
Odds ratio (90% confidence interval)	-	1.78 (1.08, 2.93)
Week 10 % remitters	40	50
Odds ratio (90% confidence interval)	-	1.46 (0.89, 2.41)
HAMD-17 (subjects with a HAMD-17 total score ≤7)		
Week 1 % remitters	2	4
Odds ratio (90% confidence interval)	-	1.68 (0.44, 6.47)
Week 2 % remitters	4	7
Odds ratio (90% confidence interval)	-	1.66 (0.60, 4.57)
Week 4 % remitters	11	13
Odds ratio (90% confidence interval)	-	1.09 (0.53,2.24)
Week 6 % remitters	18	31
Odds ratio (90% confidence interval)	-	1.89 (1.06, 3.37)
Week 8 % remitters	31	44

Odds ratio (90% confidence interval)	-	1.76 (1.05, 2.96)
Week 10 % remitters	31	55
Odds ratio (90% confidence interval)	-	2.67 (1.58, 4.52)
Time to maintained antidepressant response (at Week 10)		
IDS-CR (≥50% reduction from Randomisation in total score)		
Hazards ratio (90% confidence interval)	-	1.58 (1.12, 2.22)
HAMD-17 (≥50% reduction from Randomisation in total score)		
Hazards ratio (90% confidence interval)	-	1.54 (1.09, 2.17)
Time to maintained remission (at Week 10)		
IDS-CR (subjects with IDS total score ≤14)		
Hazards ratio (90% confidence interval)	-	1.70 (1.10, 2.62)
HAMD-17 (subjects with a HAMD-17 total score ≤7)		
Hazards ratio (90% confidence interval)	-	2.00 (1.24, 3.23)
Changes in Sexual Functioning Questionnaire		
Total score (summary statistics)		
Change from Randomisation to Week 4 (mean [SD])	2.4 (6.03)	1.6 (7.47)
Range	-18 to 18	-22 to 25
Change from Randomisation to Week 10 (mean [SD])	5.7 (9.10)	5.4 (9.66)
Range	-16 to 28	-17 to 31
Total score (MMRM analysis)		
Change from Randomisation to Week 10 (LS mean)	6.06	5.66
Difference versus placebo	-	-0.41
90% Confidence Interval	-	-2.69, 1.88
Pleasure		

Change from Randomisation to Week 4 (mean [SD])	0.4 (0.85)	0.3 (0.80)
Range	-2 to 3	-2 to 2
Change from Randomisation to Week 10 (mean [SD])	0.7 (1.06)	0.7 (1.25)
Range	-2 to 3	-3 to 4
Desire/Frequency		
Change from Randomisation to Week 4 (mean [SD])	0.4 (1.23)	0.2 (1.51)
Range	-4 to 4	-6 to 4
Change from Randomisation to Week 10 (mean [SD])	0.8 (1.95)	0.8 (1.90)
Range	-5 to 6	-4 to 5
Desire/Interest		
Change from Randomisation to Week 4 (mean [SD])	0.5 (2.00)	0.5 (2.11)
Range	-6 to 6	-6 to 8
Change from Randomisation to Week 10 (mean [SD])	1.4 (2.60)	1.3 (2.77)
Range	-7 to 7	-8 to 8
Arousal/Erection		
Change from Randomisation to Week 4 (mean [SD])	0.8 (1.81)	0.3 (2.32)
Range	-4 to 5	-8 to 8
Change from Randomisation to Week 10 (mean [SD])	1.6 (2.60)	1.3 (2.74)
Range	-6 to 8	-6 to 8
Orgasm/Ejaculation		
Change from Randomisation to Week 4 (mean [SD])	0.6 (2.25)	0.5 (2.63)
Range	-6 to 8	-6 to 8
Change from Randomisation to Week 10 (mean [SD])	1.5 (2.86)	1.3 (3.03)
Range	-5 to 9	-6 to 9

Subject satisfaction with study medication (at Week 10)		
Very dissatisfied, n (%)	11 (9)	10 (9)
Dissatisfied, n (%)	12 (10)	10 (9)
Slightly dissatisfied, n (%)	6 (5)	4 (3)
Neutral, n (%)	19 (16)	11 (9)
Slightly satisfied, n (%)	19 (16)	11 (9)
Satisfied, n (%)	32 (28)	34 (29)
Very satisfied, n (%)	17 (15)	37 (32)
% satisfied	42	61
Odds ratio (90% confidence interval)	-	2.20 (1.40, 3.47)

Safety Results: An on therapy adverse event (AE) was defined as an AE with onset on or after the start date of study medication but not later than one day after the last date of study medication. An on therapy serious adverse event (SAE) was defined as a SAE with onset on or after the start date of study medication and up to 30 days after the last dose of medication.

	Placebo (N=126)	**Venlafaxine XR (N=133)**
Most Frequent Adverse Events – On-Therapy		
Subjects with any AE(s), n (%)	77 (61)	94 (71)
Dry mouth	5 (4)	12 (9)
Headache	24 (19)	28 (21)
Nausea	14 (11)	29 (22)
Insomnia	11 (9)	7 (5)
Constipation	9 (7)	12 (9)
Tachycardia	4 (3)	4 (3)
Dizziness	11 (9)	15 (11)
Anxiety	5 (4)	3 (2)
Diarrhoea	8 (6)	8 (6)

Hyperhidrosis	3 (2)	15 (11)
Tremor	5 (4)	7 (5)
Nasopharyngitis	7 (6)	6 (5)
Fatigue	5 (4)	13 (10)

Serious Adverse Events - On-Therapy **n (%) [n considered by the investigator to be related to study medication]**			
	Placebo (N=126)	**NCE (N=134)**	**Venlafaxine XR (N=133)**
Subjects with non-fatal SAEs, n (%)	1 (<1) [0]	4 (3) [0]	0
	n (%) [related]	**n (%) [related]**	**n (%) [related]**
Bronchopneumonia	0	1 (<1) [0]	0
Intentional overdose	0	1 (<1) [0]	0
Rheumatoid arthritis	0	1 (<1) [0]	0
Depression	0	1 (<1) [0]	0
Ovarian cyst	1 (<1) [0]	0	0
Subjects with fatal SAEs, n (%)	0	0	0

Conclusion: For each of the key efficacy endpoints (change from Randomisation at Week 10 in the 6-item Bech scale from the HAMD-17 and the IDS-CR total score), venlafaxine XR was statistically significantly superior compared with placebo. The results of the secondary endpoints were consistent with those of the key endpoints. A total of 77/126 (61) subjects in the placebo group, 101/134 (75) subjects in the NCE group and 94/133 (71) subjects in the venlafaxine XR group had on-therapy AEs. The most frequently reported on-therapy AEs were headache in the placebo group, dry mouth in the NCE group and nausea in the venlafaxine XR group. One subject in the placebo group and 4 subjects in the NCE group had SAEs. There were no fatal SAEs.

Publications: None.